Gennova Biopharmaceuticals becomes a fully owned subsidiary of Emcure as a result of this strategic acquisition, centralising ...

Emcure Pharmaceuticals acquires 12.05% stake in Gennova Biopharmaceuticals from Sanjay Singh for Rs 231.87 crore; Gennova ...

Gennova is a ₹49-crore company and it mRNA business, at ₹6.47 crore, represented 0.71% of consolidated revenue of the company ...

The acquisition will be completed for an aggregate cash consideration of ₹231.87 crore, payable in one or more tranches, and ...

Emcure Pharmaceuticals IPO subscription opens with ₹582 crore raised from anchor investors. Price range set at ₹960-1,008 per ...

The acquisition includes the stake held by Gennova founder Dr Sanjay Singh and other shareholders, simplifying the unit's ...

Emcure Pharmaceuticals acquires full control of Gennova Biopharma with a ₹232 crore stake purchase, enhancing its biologics focus.

Emcure Pharmaceuticals said that its subsidiary at Gennova Biopharmaceuticals has executed a business transfer agreement for transfer of its mRNA business as a going concern on a slump sale basis to ...

The IPO of Pune-based Emcure Pharma was open for bidding July 03 and July 05, which offered its shares in the fixed price ...

Emcure Pharmaceuticals Ltd shares surged 9.91 per cent in Tuesday's trade to hit a day high of Rs 1,440.90. The stock was last seen trading 6.19 per cent up at Rs 1,392.15. At this price, it has ...

Emcure Pharmaceuticals has had its share of run-ins with the FDA in the past over the sterility of one of its Indian manufacturing plants. Now, it can notch one more black mark on its belt. The FDA ...